141 related articles for article (PubMed ID: 23544718)
1. Managed care aspects of managing multiple sclerosis.
Mathis AS
Am J Manag Care; 2013 Feb; 19(2 Suppl):S28-34. PubMed ID: 23544718
[TBL] [Abstract][Full Text] [Related]
2. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies.
Owens GM; Olvey EL; Skrepnek GH; Pill MW
J Manag Care Pharm; 2013; 19(1 Suppl A):S41-53. PubMed ID: 23383732
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study.
Tan H; Yu J; Tabby D; Devries A; Singer J
Mult Scler; 2010 Aug; 16(8):956-63. PubMed ID: 20595246
[TBL] [Abstract][Full Text] [Related]
4. Managed approaches to multiple sclerosis in special populations.
Sperandeo K; Nogrady L; Moreo K; Prostko CR
J Manag Care Pharm; 2011; 17(9 Suppl C):S1-19; quiz S20-1. PubMed ID: 22107156
[TBL] [Abstract][Full Text] [Related]
5. Implications for multiple sclerosis in the era of the Affordable Care Act: the shifting managed care landscape.
Mathis AS; Owens GM
Am J Manag Care; 2014 Dec; 20(11 Suppl):S242-53. PubMed ID: 25734889
[TBL] [Abstract][Full Text] [Related]
6. Managed care aspects of managing multiple sclerosis.
Owens GM
Am J Manag Care; 2013 Nov; 19(16 Suppl):s307-12. PubMed ID: 24494620
[TBL] [Abstract][Full Text] [Related]
7. Implications for managed care and specialty pharmacy in rheumatoid arthritis.
Cardarelli WJ
Am J Manag Care; 2012 Dec; 18(13 Suppl):S315-24. PubMed ID: 23327519
[TBL] [Abstract][Full Text] [Related]
8. DM programs take advantage of new therapies to reduce costs, complications for MS patients.
Healthc Demand Dis Manag; 1998 Jul; 4(7):106-8, 97. PubMed ID: 10186040
[TBL] [Abstract][Full Text] [Related]
9. Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis.
Bandari DS; Sternaman D; Chan T; Prostko CR; Sapir T
J Manag Care Pharm; 2012; 18(9):1-17. PubMed ID: 23206263
[TBL] [Abstract][Full Text] [Related]
10. Treat MS proactively in managed care setting.
Capitation Rates Data; 2004 Apr; 9(4):44-5. PubMed ID: 15162596
[No Abstract] [Full Text] [Related]
11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
12. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.
Phillips CJ
CNS Drugs; 2004; 18(9):561-74. PubMed ID: 15222773
[TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
14. Economic burden and current managed care challenges associated with hepatitis C.
Mathis AS
Am J Manag Care; 2012 Dec; 18(14 Suppl):S350-9. PubMed ID: 23327541
[TBL] [Abstract][Full Text] [Related]
15. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
[TBL] [Abstract][Full Text] [Related]
16. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
[TBL] [Abstract][Full Text] [Related]
18. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.
Yermakov S; Davis M; Calnan M; Fay M; Cox-Buckley B; Sarda S; Duh MS; Iyer R
J Med Econ; 2015; 18(9):711-20. PubMed ID: 25903661
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis care: an integrated disease-management model.
Burks J
J Spinal Cord Med; 1998 Apr; 21(2):113-6. PubMed ID: 9697085
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics of synthetic therapies for multiple sclerosis.
D'Amico E; Chisari CG; Gitto L; Zanghì A; Toscano S; Patti F
Expert Opin Pharmacother; 2019 Aug; 20(11):1331-1340. PubMed ID: 31090469
[No Abstract] [Full Text] [Related]
[Next] [New Search]
